Express Mail Label No.: EV942366585US 05-11-01 Date of Deposit: May 9, 2007

Attorney Docket No. 24852-505 NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Miller, et al. CONFIRMATION NUMBER: Not yet assigned

SERIAL NUMBER: 10/594,483 **EXAMINER:** Not yet assigned

FILING DATE: April 5, 2005 PCT/US05/011463 INT'L APPLICATION NO:

PRIORITY DATE: April 5, 2004 Not yet assigned ART UNIT:

> FOR: Histone Deacetylase Inhibitor Prodrugs

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages) in duplicate;
- 2. Modified Form PTO-1449 (2 pages); in duplicate;
- 3. Cited References A1-A10; B1-B6; C1-C52; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due or to credit any overpayment of same to the undersigned's account, Deposit Account No. 50-0311, Customer Number: 35437, Reference Number: 24852-505 NATL.

Respectfully submitted,

richelle A Twamois Dated: May 9, 2007

Ivor R. Elrifi, Reg. No. 39,529 Michelle A. Iwamoto, Reg. No. 55,296

Attorneys/Agents for Applicants c/o MINTZ, LEVIN, et al.

666 Third Avenue-24th Floor New York, New York 10017 Telephone: (212) 983-3000

Telefax: (212) 983-3115

Date of Deposit: May 9, 2007

Attorney Docket No. 24852-505 NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Miller, et al. CONFIRMATION NUMBER: Not yet assigned

SERIAL NUMBER: 10/594,483 EXAMINER: Not yet assigned

A. FILING DATE: April 5, 2005 INT'L APPLICATION NO: PCT/US05/011463

PRIORITY DATE: April 5, 2004 ART UNIT: Not yet assigned

FOR: Histone Deacetylase Inhibitor Prodrugs

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. In accordance with MPEP §609(III)(A)(2), copies of the cited U.S. patents and U.S. publications are not required.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Date of Deposit: May 9, 2007

Attorney Docket No. 24852-505 NATL

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24852-505 NATL, Customer No. 35437.

Respectfully submitted,

Dated: May 9, 2007

michille & Iwamoto

Ivor R. Elrifi, Reg. No. 39,529 Michelle A. Iwamoto, Reg. No. 55,296

Attorneys/Agents for Applicants c/o MINTZ, LEVIN, *et al.*

666 Third Avenue-24th Floor

New York, New York 10017 Telephone: (212) 983-3000

Telefax: (212) 983-3115

Date of Deposit: May 9, 2007

Please type a plus sign (+) in this box

PTO/SB (12-97)
OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ed Form 1449/PTO	Application Number	10/594,483	
	International Application Number	PCT/US05/011463	
	I.A. Filing Date	April 5, 2005	
INFORMATION DISCLOSURE	Priority Date	April 5, 2004	
STATEMENT BY APPLICANT	First Named Inventor Miller		
	Group Art Unit / Conf. No.:	Not Yet Assigned	
(use as many sheets as necessary)	Examiner Name	Not Yet Assigned	
	Attorney Docket Number	24852-505 NATL	
—			

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A1	4,522,811	06/11/85	Eppstein, et al.	514	2	07/08/82
	A2	5,369,108	11/29/94	Breslow, et al.	514	266	10/04/91
	A3	5,608,108	03/04/97	Marks, et al.	562	621	04/17/95
	A4	5,700,811	12/23/97	Breslow, et al.	514	314	05/19/94
	A5	5,932,616	08/03/99	Breslow, et al.	514	532	04/04/94
	A6	6,087,367	07/11/00	Breslow, et al.	514	266	05/18/99
	A7	6,511,990	01/28/03	Breslow, et al.	514	314	08/24/00
	A8	7,126,001	10/24/06	Breslow, et al.	546	171	10/25/02
	A8	2003/0235588	12/25/03	Richon, et al.	514	575	02/14/03
	A9	2004/0087657	05/06/04	Richon, et al.	514	575	10/16/02
	A10	2004/0266818	12/30/04	Breslow, et al.	514	310	04/01/04

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite Foreign Patent Document No. Office Number		•	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No	
	B1	wo	97/11366	Merck & Co., Inc.	March 27, 1977	X	
	B2	wo	98/48825	The Salk Institute for Biological Studies	November 5, 1998	X	
	B3	wo	00/08048	Fujisawa Pharmaceuticals Co., Ltd.	February 17, 2000	X	
· · · · · · · · · · · · · · · · · · ·	B4	wo	05/053610	Aton Pharma, Inc.	June 16, 2005	х	
	B5	wo	05/097747	Aton Pharma, Inc.	October 20, 2005	Х	
	B6	wo	05/348800	Aton Pharma, Inc.	April 21, 2005	Х	

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No. Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
	C1	Abe, E., et al., Proc. Natl. Acad. Sci. (USA) 78:4990-4994 (1981)			
	C2	Andrews et al., International J. Parasitology 30,761-768 (2000)			
	C3	Archer, S. et al., PNAS 95:6791-96 (1998)			
	C4	Berge, et al., J. Pharm. Sci., 66:1-19 (1977).			
	. C5	Brosch et al., Plant Cell 7, 1941-1950 (1995)			
	C6	Butler, L.M. et al., Cancer Res. 60:5165-5170 (2000)			
	C7	Cohen, L.A. et al., Anticancer Research 19:4999-5006 (1999)			
	C8	Cousens et al., J. Biol. Chem. 254,1716-1723 (1979)			
	C9	Darkin-Rattray et al., Proc. Natl. Acad. Sci. USA 93,13143-13147 (1996)			
	C10	Dressel, U. et al., Anticancer Research 20(2A):1017-22 (2000)			
	C11	Ebert, P. S., et al. Cancer Res. 36: 1809-1813 (1976)			

Date of Deposit: May 9, 2007

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C12	Finnin, M.S., et al., Nature 401:188-193 (1999)
	C13	Frey et al, Bioorganic & Med. Chem. Lett., 12, 3443-3447 (2002)
	C14	Friend, C., et al., Proc. Natl. Acad. Sci., U. S., 68:378-382 (1971)
	C15	Grunstein, M., <i>Nature</i> , 389: 349-52 (1997)
	C16	Guan et al., Cancer Research, 60,749-755 (2000)
	C17	Hayashi, M., et al., Gann 70: 235-238 (1979)
	C18	Huberman, E. et al., Proc. Natl. Acad. Sci. (USA) 76: 1293-1297 (1979)
	C19	Kijima et al., J Biol. Chem. 268,22429-22435 (1993)
	C20	Kim et al., Oncogene, 18: 2461-2470 (1999)
	C21	Koghe <i>et al.</i> , Biochem. Pharmacol. 56: 1359-1364 (1998)
	C22	Kwon et al., PNAS 95: 3356-3361 (1998)
	C23	Lea et al., Anticancer Research, 15, 879-873 (1995)
	C24	Lin, R.J. et al., Nature 391:811-14 (1998)
	C25	Lotem, J., et al., Int. J. Cancer 15: 731-740 (1975)
	C26	Lotem, J. et al., Proc. Natl. Acad. Sci. (USA) 76: 5158-5162 (1979)
	C27	Marks, P. et al., Cancer Res. 47:659 (1987)
······································	C28	Marks, P.A. et al., J. Natl. Cancer Inst., 92:1210-1215 (2000)
	C29	McBain et al., Biochem. Pharm. 53: 1357-1368 (1997)
	C30	Metcalf, D., et al., Science, 229: 16-22 (1985)
	C31	Morin, M. J., et al., Cancer Res. 44: 2807-2812 (1984)
	C32	Nakajima et al., Ex. Cell Res. 241,126-133 (1998)
	C33	Qiu et al., Mol. Biol. Cell 11, 2069-2083 (2000)
	C34	Reuben, R. C., et al., Proc. Natl. Acad. Sci. (USA) 73: 862-866 (1976)
	C35	Richon et al., Proc. Natl. Acad. Sci. USA, 93:5705-5708 (1996)
	C36	Richon, V. M. et al., Proc. Natl. Acad. Sci., USA, 95:3003-3007 (1998)
	C37	Sachs, L., Nature (Lond.) 274: 535 (1978)
	C38	Saito et al., Proc. Natl. Acad. Sci. USA 96, 4592-4597 (1999)
	C39	Scher, W. et al., Exp. Hematol. 11: 490-498 (1983)
	C40	Scher, W., et al., Biochem. & Biophys. Res. Comm. 109: 348-354) (1982)
	C41	Schwartz, E. L. et al., Cancer Res. 42: 2651-2655 (1982)
	C42	Schwartz, E. L., et al., Cancer Res. 43: 2725-2730 (1983)
	C43	Schwartz, E. L., et al., Proc. Am. Assoc. Cancer Res. 24: 18 (1983)
	C44	Su et al., Cancer Research, 60: 3137-3142 (2000)
	C45	Sugano, H., et al., Bibl. Hematol. 39: 943-954 (1973)
	C46	Takenaga, K., et al., Cancer Res. 40: 914-919 (1980)
	C47	Tanaka, M., et al., Proc. Natl. Acad. Sci. (USA) 72: 1003-1006 (1975)
	C48	Terada, M., et al., Proc. Natl. Acad. Sci. (USA) 75: 2795-2799 (1978)
	C49	Van Lint, C. et al., Gene Expression 5:245-53 (1996)
	C50	Wang et al., Cancer Research 59, 2766-2799 (1999)
	C51	Yoshida, M. et al., J. Biol. Chem. 265:17174-17179, (1990)
	C52	International Search Report for PCT/US05/011463 mailed July 26, 2005

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No, filed, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).								
Examiner Signature		Date Considered						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.